Publication Information

{'id': 'https://openalex.org/W4367296034', 'doi': 'https://doi.org/10.1212/wnl.0000000000202412', 'title': 'Safety and Efficacy of Inebilizumab in AQP4+ NMOSD Participants with History of Immunosuppression Treatment Prior to N-MOmentum Study (P13-5.003)', 'display_name': 'Safety and Efficacy of Inebilizumab in AQP4+ NMOSD Participants with History of Immunosuppression Treatment Prior to N-MOmentum Study (P13-5.003)', 'publication_year': 2023, 'publication_date': '2023-04-25', 'ids': {'openalex': 'https://openalex.org/W4367296034', 'doi': 'https://doi.org/10.1212/wnl.0000000000202412'}, 'language': 'en', 'primary_location': {'is_oa': False, 'landing_page_url': 'https://doi.org/10.1212/wnl.0000000000202412', 'pdf_url': None, 'source': {'id': 'https://openalex.org/S79704628', 'display_name': 'Neurology', 'issn_l': '0028-3878', 'issn': ['0028-3878', '1526-632X'], 'is_oa': False, 'is_in_doaj': False, 'is_core': True, 'host_organization': 'https://openalex.org/P4310315671', 'host_organization_name': 'Lippincott Williams & Wilkins', 'host_organization_lineage': ['https://openalex.org/P4310315671', 'https://openalex.org/P4310318547'], 'host_organization_lineage_names': ['Lippincott Williams & Wilkins', 'Wolters Kluwer'], 'type': 'journal'}, 'license': None, 'license_id': None, 'version': None, 'is_accepted': False, 'is_published': False}, 'type': 'article', 'type_crossref': 'journal-article', 'indexed_in': ['crossref'], 'open_access': {'is_oa': False, 'oa_status': 'closed', 'oa_url': None, 'any_repository_has_fulltext': False}, 'authorships': [{'author_position': 'first', 'author': {'id': 'https://openalex.org/A5056912783', 'display_name': 'Friedemann Paul', 'orcid': 'https://orcid.org/0000-0002-6378-0070'}, 'institutions': [{'id': 'https://openalex.org/I7877124', 'display_name': 'Charité - Universitätsmedizin Berlin', 'ror': 'https://ror.org/001w7jn25', 'country_code': 'DE', 'type': 'healthcare', 'lineage': ['https://openalex.org/I7877124']}], 'countries': ['DE'], 'is_corresponding': False, 'raw_author_name': 'Friedemann Paul', 'raw_affiliation_strings': ['Charite Universitatsmedizin in Berlin'], 'affiliations': [{'raw_affiliation_string': 'Charite Universitatsmedizin in Berlin', 'institution_ids': ['https://openalex.org/I7877124']}]}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5002448849', 'display_name': 'Roman Marignier', 'orcid': None}, 'institutions': [{'id': 'https://openalex.org/I4210100596', 'display_name': 'Hospices Civils de Lyon', 'ror': 'https://ror.org/01502ca60', 'country_code': 'FR', 'type': 'healthcare', 'lineage': ['https://openalex.org/I4210100596']}], 'countries': ['FR'], 'is_corresponding': False, 'raw_author_name': 'Roman Marignier', 'raw_affiliation_strings': ['Hospices Civils de Lyon'], 'affiliations': [{'raw_affiliation_string': 'Hospices Civils de Lyon', 'institution_ids': ['https://openalex.org/I4210100596']}]}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5035116666', 'display_name': 'John Lindsey', 'orcid': 'https://orcid.org/0000-0001-6856-0811'}, 'institutions': [{'id': 'https://openalex.org/I919571938', 'display_name': 'The University of Texas Health Science Center at Houston', 'ror': 'https://ror.org/03gds6c39', 'country_code': 'US', 'type': 'education', 'lineage': ['https://openalex.org/I919571938']}], 'countries': ['US'], 'is_corresponding': False, 'raw_author_name': 'John Lindsey', 'raw_affiliation_strings': ['University of Texas Health Science Center At Houston'], 'affiliations': [{'raw_affiliation_string': 'University of Texas Health Science Center At Houston', 'institution_ids': ['https://openalex.org/I919571938']}]}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5110592992', 'display_name': 'Ho Jin Kim', 'orcid': None}, 'institutions': [], 'countries': [], 'is_corresponding': False, 'raw_author_name': 'Ho Jin Kim', 'raw_affiliation_strings': ['National Cancer Center'], 'affiliations': [{'raw_affiliation_string': 'National Cancer Center', 'institution_ids': []}]}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5111211413', 'display_name': 'Dewei She', 'orcid': None}, 'institutions': [{'id': 'https://openalex.org/I4210087770', 'display_name': 'Horizon Therapeutics (United Kingdom)', 'ror': 'https://ror.org/003mr9q86', 'country_code': 'IE', 'type': 'company', 'lineage': ['https://openalex.org/I4210087770', 'https://openalex.org/I4210094550']}], 'countries': ['IE'], 'is_corresponding': False, 'raw_author_name': 'Dewei She', 'raw_affiliation_strings': ['Horizon Therapeutics plc'], 'affiliations': [{'raw_affiliation_string': 'Horizon Therapeutics plc', 'institution_ids': ['https://openalex.org/I4210087770']}]}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5111765614', 'display_name': 'Daniel Cimbora', 'orcid': 'https://orcid.org/0000-0001-9835-1527'}, 'institutions': [{'id': 'https://openalex.org/I4210087770', 'display_name': 'Horizon Therapeutics (United Kingdom)', 'ror': 'https://ror.org/003mr9q86', 'country_code': 'IE', 'type': 'company', 'lineage': ['https://openalex.org/I4210087770', 'https://openalex.org/I4210094550']}], 'countries': ['IE'], 'is_corresponding': False, 'raw_author_name': 'Daniel Cimbora', 'raw_affiliation_strings': ['Horizon Therapeutics plc'], 'affiliations': [{'raw_affiliation_string': 'Horizon Therapeutics plc', 'institution_ids': ['https://openalex.org/I4210087770']}]}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5060600260', 'display_name': 'Kristina Patterson', 'orcid': None}, 'institutions': [{'id': 'https://openalex.org/I4210087770', 'display_name': 'Horizon Therapeutics (United Kingdom)', 'ror': 'https://ror.org/003mr9q86', 'country_code': 'IE', 'type': 'company', 'lineage': ['https://openalex.org/I4210087770', 'https://openalex.org/I4210094550']}], 'countries': ['IE'], 'is_corresponding': False, 'raw_author_name': 'Kristina Patterson', 'raw_affiliation_strings': ['Horizon Therapeutics plc'], 'affiliations': [{'raw_affiliation_string': 'Horizon Therapeutics plc', 'institution_ids': ['https://openalex.org/I4210087770']}]}, {'author_position': 'last', 'author': {'id': 'https://openalex.org/A5075425414', 'display_name': 'Bruce Cree', 'orcid': None}, 'institutions': [{'id': 'https://openalex.org/I2799371350', 'display_name': 'Multiple Sclerosis Foundation', 'ror': 'https://ror.org/049fh2r80', 'country_code': 'US', 'type': 'nonprofit', 'lineage': ['https://openalex.org/I2799371350']}], 'countries': ['US'], 'is_corresponding': False, 'raw_author_name': 'Bruce Cree', 'raw_affiliation_strings': ['UCSF, Multiple Sclerosis Center'], 'affiliations': [{'raw_affiliation_string': 'UCSF, Multiple Sclerosis Center', 'institution_ids': ['https://openalex.org/I2799371350']}]}], 'institution_assertions': [], 'countries_distinct_count': 4, 'institutions_distinct_count': 5, 'corresponding_author_ids': [], 'corresponding_institution_ids': [], 'apc_list': None, 'apc_paid': None, 'fwci': 0.0, 'has_fulltext': False, 'cited_by_count': 0, 'citation_normalized_percentile': {'value': 0.0, 'is_in_top_1_percent': False, 'is_in_top_10_percent': False}, 'cited_by_percentile_year': {'min': 0, 'max': 67}, 'biblio': {'volume': '100', 'issue': '17_supplement_2', 'first_page': None, 'last_page': None}, 'is_retracted': False, 'is_paratext': False, 'primary_topic': {'id': 'https://openalex.org/T10580', 'display_name': 'Immunotherapy and Immune Responses', 'score': 0.9605, 'subfield': {'id': 'https://openalex.org/subfields/2403', 'display_name': 'Immunology'}, 'field': {'id': 'https://openalex.org/fields/24', 'display_name': 'Immunology and Microbiology'}, 'domain': {'id': 'https://openalex.org/domains/1', 'display_name': 'Life Sciences'}}, 'topics': [{'id': 'https://openalex.org/T10580', 'display_name': 'Immunotherapy and Immune Responses', 'score': 0.9605, 'subfield': {'id': 'https://openalex.org/subfields/2403', 'display_name': 'Immunology'}, 'field': {'id': 'https://openalex.org/fields/24', 'display_name': 'Immunology and Microbiology'}, 'domain': {'id': 'https://openalex.org/domains/1', 'display_name': 'Life Sciences'}}, {'id': 'https://openalex.org/T11725', 'display_name': 'Immunodeficiency and Autoimmune Disorders', 'score': 0.9588, 'subfield': {'id': 'https://openalex.org/subfields/2403', 'display_name': 'Immunology'}, 'field': {'id': 'https://openalex.org/fields/24', 'display_name': 'Immunology and Microbiology'}, 'domain': {'id': 'https://openalex.org/domains/1', 'display_name': 'Life Sciences'}}, {'id': 'https://openalex.org/T10602', 'display_name': 'Glycosylation and Glycoproteins Research', 'score': 0.9573, 'subfield': {'id': 'https://openalex.org/subfields/1312', 'display_name': 'Molecular Biology'}, 'field': {'id': 'https://openalex.org/fields/13', 'display_name': 'Biochemistry, Genetics and Molecular Biology'}, 'domain': {'id': 'https://openalex.org/domains/1', 'display_name': 'Life Sciences'}}], 'keywords': [{'id': 'https://openalex.org/keywords/immunosuppression', 'display_name': 'Immunosuppression', 'score': 0.64599407}, {'id': 'https://openalex.org/keywords/neuromyelitis-optica', 'display_name': 'Neuromyelitis Optica', 'score': 0.6204022}], 'concepts': [{'id': 'https://openalex.org/C71924100', 'wikidata': 'https://www.wikidata.org/wiki/Q11190', 'display_name': 'Medicine', 'level': 0, 'score': 0.8088081}, {'id': 'https://openalex.org/C2780252810', 'wikidata': 'https://www.wikidata.org/wiki/Q1455316', 'display_name': 'Immunosuppression', 'level': 2, 'score': 0.64599407}, {'id': 'https://openalex.org/C2781137167', 'wikidata': 'https://www.wikidata.org/wiki/Q611458', 'display_name': 'Neuromyelitis optica', 'level': 3, 'score': 0.6204022}, {'id': 'https://openalex.org/C2776760755', 'wikidata': 'https://www.wikidata.org/wiki/Q18939', 'display_name': 'Azathioprine', 'level': 3, 'score': 0.5834891}, {'id': 'https://openalex.org/C126322002', 'wikidata': 'https://www.wikidata.org/wiki/Q11180', 'display_name': 'Internal medicine', 'level': 1, 'score': 0.52661926}, {'id': 'https://openalex.org/C168563851', 'wikidata': 'https://www.wikidata.org/wiki/Q1436668', 'display_name': 'Randomized controlled trial', 'level': 2, 'score': 0.4567808}, {'id': 'https://openalex.org/C27081682', 'wikidata': 'https://www.wikidata.org/wiki/Q269829', 'display_name': 'Placebo', 'level': 3, 'score': 0.4533363}, {'id': 'https://openalex.org/C2777288759', 'wikidata': 'https://www.wikidata.org/wiki/Q4164182', 'display_name': 'Dosing', 'level': 2, 'score': 0.44417107}, {'id': 'https://openalex.org/C187212893', 'wikidata': 'https://www.wikidata.org/wiki/Q123028', 'display_name': 'Pediatrics', 'level': 1, 'score': 0.38559902}, {'id': 'https://openalex.org/C2780640218', 'wikidata': 'https://www.wikidata.org/wiki/Q8277', 'display_name': 'Multiple sclerosis', 'level': 2, 'score': 0.25853363}, {'id': 'https://openalex.org/C203014093', 'wikidata': 'https://www.wikidata.org/wiki/Q101929', 'display_name': 'Immunology', 'level': 1, 'score': 0.22014725}, {'id': 'https://openalex.org/C2779134260', 'wikidata': 'https://www.wikidata.org/wiki/Q12136', 'display_name': 'Disease', 'level': 2, 'score': 0.06789559}, {'id': 'https://openalex.org/C204787440', 'wikidata': 'https://www.wikidata.org/wiki/Q188504', 'display_name': 'Alternative medicine', 'level': 2, 'score': 0.0}, {'id': 'https://openalex.org/C142724271', 'wikidata': 'https://www.wikidata.org/wiki/Q7208', 'display_name': 'Pathology', 'level': 1, 'score': 0.0}], 'mesh': [], 'locations_count': 1, 'locations': [{'is_oa': False, 'landing_page_url': 'https://doi.org/10.1212/wnl.0000000000202412', 'pdf_url': None, 'source': {'id': 'https://openalex.org/S79704628', 'display_name': 'Neurology', 'issn_l': '0028-3878', 'issn': ['0028-3878', '1526-632X'], 'is_oa': False, 'is_in_doaj': False, 'is_core': True, 'host_organization': 'https://openalex.org/P4310315671', 'host_organization_name': 'Lippincott Williams & Wilkins', 'host_organization_lineage': ['https://openalex.org/P4310315671', 'https://openalex.org/P4310318547'], 'host_organization_lineage_names': ['Lippincott Williams & Wilkins', 'Wolters Kluwer'], 'type': 'journal'}, 'license': None, 'license_id': None, 'version': None, 'is_accepted': False, 'is_published': False}], 'best_oa_location': None, 'sustainable_development_goals': [{'id': 'https://metadata.un.org/sdg/3', 'score': 0.85, 'display_name': 'Good health and well-being'}], 'grants': [], 'datasets': [], 'versions': [], 'referenced_works_count': 0, 'referenced_works': [], 'related_works': ['https://openalex.org/W4232027796', 'https://openalex.org/W4230236810', 'https://openalex.org/W2905461857', 'https://openalex.org/W2625404774', 'https://openalex.org/W2407005346', 'https://openalex.org/W2286262296', 'https://openalex.org/W2107941546', 'https://openalex.org/W2040914342', 'https://openalex.org/W2025863666', 'https://openalex.org/W171560159'], 'abstract_inverted_index': {'<h3>Objective:</h3>': [0], 'To': [1], 'evaluate': [2], 'long-term': [3, 279], 'outcomes': [4, 280], 'of': [5, 19, 37, 64, 76, 94, 120, 125, 165, 226, 241, 245, 250, 281, 308, 318, 332, 342, 361, 385, 409, 434, 459, 483, 502, 521, 540, 560, 579, 598, 617, 630, 640, 665, 683, 701, 719, 738, 762, 780, 800, 819, 837, 849, 867, 889, 917, 936, 950, 964, 990, 992, 995, 1006, 1016, 1027, 1037, 1048, 1058, 1070, 1080, 1091, 1101, 1112, 1122, 1134, 1144, 1155, 1165, 1176, 1186, 1204, 1223, 1241, 1259, 1278, 1296, 1314, 1332, 1350], 'inebilizumab': [6, 77, 112, 153, 166, 282], 'treatment': [7, 36, 93, 124, 167], 'in': [8, 43, 168, 236, 283, 315, 339, 358, 382, 406, 431, 456, 480, 499, 518, 537, 557, 576, 595, 614, 637, 662, 680, 698, 716, 735, 759, 777, 797, 816, 834, 864, 886, 914, 1001, 1013, 1034, 1055, 1077, 1098, 1119, 1141, 1162, 1183, 1201, 1220, 1238, 1256, 1275, 1293, 1311, 1329], 'AQP4<sup>+</sup>': [9, 108, 284], 'NMOSD': [10, 95, 127, 285], 'participants': [11, 60, 109, 188, 227, 286, 300], 'from': [12, 856, 976, 1357, 1365], 'the': [13, 35, 54, 90, 169, 316, 340, 359, 383, 407, 432, 457, 481, 500, 519, 538, 558, 577, 596, 615, 638, 663, 681, 699, 717, 736, 760, 778, 798, 817, 835, 865, 887, 915, 993, 1014, 1035, 1056, 1078, 1099, 1120, 1142, 1163, 1184, 1202, 1221, 1239, 1257, 1276, 1294, 1312, 1330], 'N-MOmentum': [14, 55], 'trial': [15, 75], 'with': [16, 80, 189, 228, 288], 'a': [17, 62, 73, 293, 323, 347, 366, 390, 414, 439, 464, 488, 507, 526, 545, 565, 584, 603, 622, 670, 688, 706, 724, 743, 767, 785, 805, 824, 872, 894, 1021, 1042, 1063, 1085, 1106, 1127, 1149, 1170, 1191, 1209, 1228, 1246, 1264, 1283, 1301, 1319, 1337, 1366], 'history': [18, 63, 119], 'immunosuppressant': [20, 65, 303], 'therapy': [21, 66, 122, 291], 'as': [22, 146, 148, 299, 322, 346, 644, 669, 687, 705, 723, 766, 784, 804, 823, 841, 871, 921, 947, 961, 987, 1020, 1041, 1062, 1084, 1105, 1126, 1148, 1169, 1190, 1208, 1227, 1245, 1263, 1282, 1300, 1318], 'compared': [23, 195], 'to': [24, 100, 196, 1369], 'those': [25], 'without.': [26], '<h3>Background:</h3>': [27], 'Inebilizumab': [28], '(anti-CD19': [29], 'B-cell-depleting': [30], 'antibody)': [31], 'is': [32], 'approved': [33], 'for': [34, 46, 89, 175, 187, 200, 212, 222, 261, 266, 271, 320, 325, 344, 349, 363, 374, 387, 398, 411, 422, 436, 447, 461, 472, 485, 491, 504, 510, 523, 529, 542, 548, 562, 568, 581, 587, 600, 606, 619, 625, 642, 654, 667, 672, 685, 690, 703, 708, 721, 726, 740, 751, 764, 769, 782, 787, 802, 807, 821, 826, 839, 845, 869, 874, 891, 897, 919, 931, 945, 959, 985, 1018, 1023, 1039, 1044, 1060, 1065, 1082, 1087, 1103, 1108, 1124, 1129, 1146, 1151, 1167, 1172, 1188, 1193, 1206, 1211, 1225, 1230, 1243, 1248, 1261, 1266, 1280, 1285, 1298, 1303, 1316, 1321, 1334, 1345], 'neuromyelitis': [38], 'optica': [39], 'spectrum': [40], 'disorder': [41], '(NMOSD)': [42], 'adults': [44], 'seropositive': [45], 'aquaporin-4': [47], 'antibody': [48], '(AQP4<sup>+</sup>).': [49], 'Immunosuppressants': [50], 'were': [51, 115, 160, 259], 'prohibited': [52], 'during': [53], 'pivotal': [56], 'trial,': [57], 'although': [58], 'many': [59], 'had': [61], 'before': [67], 'enrolment.': [68], '<h3>Design/Methods:</h3>': [69], 'N-Momentum': [70], '(NCT02200770)': [71], 'was': [72, 97, 172, 191, 214, 233], '28-week-randomized-phase-2/3': [74], 'vs': [78], 'placebo,': [79], 'an': [81, 645, 842, 922, 948, 962, 973, 988], 'optional': [82], 'Open-Label-Extension': [83], '(OLE)': [84], '(&gt;2': [85], 'years).': [86], 'Immunosuppressant': [87], 'medication': [88], 'prevention': [91], 'or': [92, 130, 369, 393, 417, 442, 467, 649, 746, 926, 972, 1340], 'relapses': [96], 'allowed': [98], 'prior': [99, 131, 289, 302], 'dosing': [101], 'on': [102, 365, 389, 413, 438, 463, 487, 506, 525, 544, 564, 583, 602, 621, 742, 893, 1336], 'Day': [103], '1.': [104], 'In': [105], 'this': [106], 'analysis,': [107], 'who': [110], 'received': [111, 156, 312, 336, 355, 379, 403, 428, 453, 477, 496, 515, 534, 554, 573, 592, 611, 634, 659, 677, 695, 713, 732, 756, 774, 794, 813, 831, 853, 861, 883, 911, 942, 956, 970, 982, 1010, 1031, 1052, 1074, 1095, 1116, 1138, 1159, 1180, 1198, 1217, 1235, 1253, 1272, 1290, 1308, 1326, 1354, 1362], '(through': [113], 'OLE)': [114], 'grouped': [116], 'by': [117], 'no': [118], 'immunosuppression': [121], 'beyond': [123], 'acute': [126], 'attacks': [128], '(naïve),': [129], 'azathioprine': [132], '(AZA)': [133], 'and/or': [134], 'mycophenolate': [135], 'mofetil': [136], '(MMF)': [137], 'therapy.': [138, 304], 'Outcomes': [139], 'included': [140], 'annualized': [141, 180, 203], 'relapse': [142, 181], 'and': [143, 158, 174, 218, 238, 247, 268, 296], 'hospitalization': [144, 206], 'rates,': [145], 'well': [147], 'safety': [149, 297], 'assessments.': [150], '<h3>Results:</h3>': [151], 'Among': [152], 'participants,': [154, 177], '94': [155], 'prior-AZA/MMF': [157, 170, 190, 213, 237, 246, 267], '103': [159], 'immunosuppressant-naïve.': [161], 'The': [162, 179, 202, 224, 306, 330, 628, 847, 1004, 1025, 1046, 1068, 1089, 1110, 1132, 1153, 1174, 1348], 'total': [163], 'patient-years': [164], 'group': [171], '300.35': [173], 'immunosuppressant-naïve': [176, 251], '335.7.': [178], 'rate': [182, 207, 209], '(95%': [183], 'confidence': [184], 'interval': [185], '[CI])': [186], '0.11': [192], '(0.07,': [193], '0.17),': [194], '0.08': [197], '(0.05,': [198], '0.14)': [199], 'naïve.': [201, 223], 'NMOSD-related': [204], 'inpatient': [205], '(annualized': [208], '[95%': [210], 'CI])': [211], '0.15': [215], '(0.08,': [216], '0.27),': [217], '0.12': [219], '(0.06,': [220], '0.22)': [221], 'percentage': [225], '≥1': [229, 253], 'study': [230, 254], 'drug-related-treatment-emergent-adverse-event': [231], '(TEAE)': [232], '30.9%': [234], '(29/94)': [235], '46.6%': [239], '(49/103)': [240], 'naïve;': [242], '4.3%': [243], '(4)': [244], '5.8%': [248], '(6)': [249], 'reported': [252], 'drug-related-serious-adverse-event.': [255], 'Most': [256], 'adverse': [257], 'events': [258], 'infection-related': [260], 'both': [262], 'groups;': [263], '(72.3%': [264], '(68/94)': [265], '76.7%': [269], '(79/94)': [270], 'naïve).': [272], '<h3>Conclusions:</h3>': [273], 'This': [274], 'post': [275], 'hoc': [276], 'analysis': [277], 'evaluating': [278], 'treated': [287], 'AZA/MMF': [290], 'demonstrated': [292], 'similar': [294], 'efficacy': [295], 'profile': [298], 'without': [301], '<b>Disclosure:</b>': [305], 'institution': [307, 331, 629, 848, 1005, 1026, 1047, 1069, 1090, 1111, 1133, 1154, 1175, 1349], 'Dr.': [309, 333, 352, 376, 400, 425, 450, 474, 493, 512, 531, 551, 570, 589, 608, 631, 656, 674, 692, 710, 729, 753, 771, 791, 810, 828, 850, 858, 880, 908, 953, 967, 979, 997, 1007, 1028, 1049, 1071, 1092, 1113, 1135, 1156, 1177, 1195, 1214, 1232, 1250, 1269, 1287, 1305, 1323, 1351, 1359], 'Paul': [310, 334, 353, 377, 401, 426, 451, 475, 494, 513, 532, 552, 571, 590, 609, 632], 'has': [311, 335, 354, 378, 402, 427, 452, 476, 495, 514, 533, 553, 572, 591, 610, 633, 658, 676, 694, 712, 731, 755, 773, 793, 812, 830, 852, 860, 882, 910, 941, 955, 969, 981, 999, 1009, 1030, 1051, 1073, 1094, 1115, 1137, 1158, 1179, 1197, 1216, 1234, 1252, 1271, 1289, 1307, 1325, 1353, 1361], 'personal': [313, 337, 356, 380, 404, 429, 454, 478, 497, 516, 535, 555, 574, 593, 612, 635, 660, 678, 696, 714, 733, 757, 775, 795, 814, 832, 862, 884, 912, 943, 957, 983, 1011, 1032, 1053, 1075, 1096, 1117, 1139, 1160, 1181, 1199, 1218, 1236, 1254, 1273, 1291, 1309, 1327], 'compensation': [314, 338, 357, 381, 405, 430, 455, 479, 498, 517, 536, 556, 575, 594, 613, 636, 661, 679, 697, 715, 734, 758, 776, 796, 815, 833, 863, 885, 913, 944, 958, 984, 1012, 1033, 1054, 1076, 1097, 1118, 1140, 1161, 1182, 1200, 1219, 1237, 1255, 1274, 1292, 1310, 1328], 'range': [317, 341, 360, 384, 408, 433, 458, 482, 501, 520, 539, 559, 578, 597, 616, 639, 664, 682, 700, 718, 737, 761, 779, 799, 818, 836, 866, 888, 916, 1015, 1036, 1057, 1079, 1100, 1121, 1143, 1164, 1185, 1203, 1222, 1240, 1258, 1277, 1295, 1313, 1331], '$500-$4,999': [319, 343, 362, 386, 435, 460, 484, 503, 522, 541, 561, 580, 599, 618, 641, 666, 702, 720, 739, 763, 781, 801, 820, 868, 890, 1102, 1145, 1166, 1187, 1205, 1242, 1260, 1279, 1297, 1315, 1333], 'serving': [321, 345, 364, 388, 412, 437, 462, 486, 505, 524, 543, 563, 582, 601, 620, 643, 668, 686, 704, 722, 741, 765, 783, 803, 822, 840, 870, 892, 920, 946, 960, 986, 1019, 1040, 1061, 1083, 1104, 1125, 1147, 1168, 1189, 1207, 1226, 1244, 1262, 1281, 1299, 1317, 1335], 'Consultant': [324, 348, 671, 689, 707, 725, 768, 786, 806, 825, 873, 1022, 1043, 1064, 1086, 1107, 1128, 1150, 1171, 1192, 1210, 1229, 1247, 1265, 1284, 1302, 1320], 'Mitsubishi': [326], 'Tanabe': [327], 'PC': [328], '(MTPC).': [329], 'Aarhus': [350], 'University.': [351], 'Scientific': [367, 391, 415, 440, 465, 744, 1338], 'Advisory': [368, 392, 416, 441, 466, 651, 745, 928, 1339], 'Data': [370, 394, 418, 443, 468, 747, 1341], 'Safety': [371, 395, 419, 444, 469, 748, 1342], 'Monitoring': [372, 396, 420, 445, 470, 749, 1343], 'board': [373, 397, 421, 446, 471, 750, 1344], 'Alexion.': [375, 569, 1194], 'Roche.': [399, 588], '$0-$499': [410, 684], 'Sanofi': [423, 905], 'Genzyme.': [424], 'UCB': [448], 'Pharma.': [449, 1268], 'CELGENE.': [473], 'Speakers': [489, 508, 527, 546, 566, 585, 604, 623, 895], 'Bureau': [490, 509, 528, 547, 567, 586, 605, 624, 896], 'Bayer.': [492], 'Novartis.': [511, 1088], 'ACRELION.': [530], 'Viela': [549, 878, 965, 977], 'Bio.': [550, 879, 966, 978, 1213], 'Pfizter.': [607], 'Merck': [626, 902], 'Serono.': [627, 1067], 'Editor,': [646, 648, 923, 925], 'Associate': [647, 924], 'Editorial': [650, 927], 'Board': [652, 929], 'Member': [653, 930], 'Springer.': [655], 'Marignier': [657, 675, 693, 711, 730], 'UCB.': [673], 'ALEXION.': [691], 'ROCHE.': [709, 752], 'HORIZON': [727], 'THERAPEUTICS.': [728], 'Lindsey': [754, 772, 792, 811, 829, 851], 'Genentech.': [770, 857, 1358], 'Banner': [788], 'Life': [789], 'Sciences.': [790], 'TG': [808, 1130], 'Therapeutics.': [809, 952, 1003, 1131], 'Mapi.': [827], '$10,000-$49,999': [838, 1059, 1081], 'Expert': [843], 'Witness': [844], 'Teva.': [846], 'research': [854, 1355], 'support': [855, 1356], 'Kim': [859, 881, 909], 'Aprilbio,': [875], 'HanAll': [876], 'BioPharma,': [877], 'Alexion,': [898], 'Biogen,': [899], 'Celltrion,': [900], 'Eisai,': [901], 'Serono,': [903], 'Novartis,': [904], 'Genzyme,': [906], 'Teva-Handok.': [907], '$5,000-$9,999': [918, 1017, 1038, 1123, 1224], 'Multiple': [932], 'Sclerosis': [933], 'Journal,': [934], 'Journal': [935], 'Clinical': [937], 'Neurology.': [938], 'Dewei': [939], 'She': [940], 'employee': [949, 963, 989], 'Horizon': [951, 1002], 'Cimbora': [954, 968], 'stock': [971, 1000], 'ownership': [974], 'interest': [975], 'Patterson': [980, 998], 'Hospital': [991], 'University': [994], 'Pennsylvania.': [996], 'Cree': [1008, 1029, 1050, 1072, 1093, 1114, 1136, 1157, 1178, 1196, 1215, 1233, 1251, 1270, 1288, 1306, 1324, 1352, 1360], 'Atara.': [1024], 'Biogen.': [1045], 'EMD': [1066], 'Sanofi.': [1109], 'Autobahn.': [1152], 'Avotres.': [1173], 'Gossamer': [1212], 'Horizon.': [1231], 'Neuron23.': [1249], 'Boston': [1267], 'Hexal/Sandoz.': [1286], 'Siemens.': [1304], 'Therini.': [1322], 'Immunic': [1346], 'AG.': [1347], 'publishing': [1363], 'royalties': [1364], 'publication': [1367], 'relating': [1368], 'health': [1370], 'care.': [1371]}, 'cited_by_api_url': 'https://api.openalex.org/works?filter=cites:W4367296034', 'counts_by_year': [], 'updated_date': '2025-01-09T21:51:28.179968', 'created_date': '2023-04-29'}